Showing all 8 resultsSorted by popularity
End of content
End of content
Peptide Research Database
For Research Use Only. Not for Human or Veterinary Use.
Incretin-based receptor agonists studied in metabolic research — the dual GIP/GLP-1 agonist tirzepatide, the triple GIP/GLP-1/glucagon agonist retatrutide and the selective GLP-1 agonist semaglutide, with a side-by-side comparison matrix.
| Compound | Class | Mechanism | Primary research targets |
|---|---|---|---|
| Tirzepatide | GIP/GLP-1 dual agonist | GIP / GLP-1 dual agonist | Type-2-diabetes and obesity metabolic research |
| Retatrutide | GIP/GLP-1/GCGR triagonist | GIP / GLP-1 / glucagon triple agonist | Obesity and energy-expenditure research |
| Semaglutide | GLP-1 receptor agonist | Selective GLP-1 agonist | Glycemic control, weight and cardiovascular research |
GLP-1 receptor agonists bind and activate the GLP-1 receptor (GLP-1R) — a class-B G-protein-coupled receptor expressed in the pancreas, brain, gastrointestinal tract and peripheral tissues — coupling through Gαs to raise cAMP. Endogenous GLP-1 is released by intestinal L-cells after eating.
Receptor binding affinities — which receptors each compound engages (approximate EC50 from published receptor pharmacology):
| Compound | GLP-1R | GIP receptor | Glucagon receptor |
|---|---|---|---|
| Tirzepatide | Active (~0.06 nM) | Active (~0.29 nM) | Inactive |
| Retatrutide | Active (~0.09 nM) | Active (~0.12 nM) | Active (~0.26 nM) |
| Semaglutide | Active (~0.04 nM) | Inactive | Inactive |
| Parameter | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Half-life | ~ 5 days | ~ 6 days | ~ 7 days (oral ~1 week) |
| Route | Subcutaneous (weekly) | Subcutaneous (weekly) | Subcutaneous (weekly) / oral (daily) |
| Bioavailability | ~ 80% (SC) | ~ 75% (SC) | ~ 89% (SC) / ~1% (oral) |
| Molecular weight | 4813.5 Da | ≈ 4840.6 Da | 4113.6 Da |
| Time to peak (Tmax) | 8–24 h | 12–24 h | 12–24 h |
| Metabolism / clearance | Proteolytic degradation | Proteolytic degradation | Proteolytic degradation |
Preclinical research:
Superior weight loss and glycemic control versus selective GLP-1R agonists in rodent models; dual GIP agonism enhances energy expenditure (Coskun et al., 2018).
Additive triple-agonism effects on body-weight reduction and glucose tolerance in diet-induced obese mice (Coskun et al., 2022).
Dose-dependent HbA1c and body-weight reductions across preclinical models; arcuate-nucleus GLP-1R mediates appetite suppression (Secher et al., 2014).
Published research — clinical-trial programs (headline results are established published data):
| Trial program | Phase | Focus | Reference |
|---|---|---|---|
| SURPASS (Tirzepatide) | Phase 3 | Glycemic control in type-2-diabetes; head-to-head vs semaglutide | Frías JP et al., Lancet 2021 |
| SURMOUNT (Tirzepatide) | Phase 3 | Body-weight reduction in obesity | Jastreboff AM et al., NEJM 2022 |
| TRIUMPH (Retatrutide) | Phase 2/3 | Body-weight reduction in obesity | Jastreboff AM et al., NEJM 2023 |
| STEP (Semaglutide) | Phase 3 | Body-weight reduction in obesity | Wilding JPH et al., NEJM 2021 |
| SUSTAIN-6 / SELECT (Semaglutide) | Phase 3 | Cardiovascular outcomes | Marso SP et al., NEJM 2016 |
Reconstitution-oriented reference figures for laboratory research only — not human dosing guidance.
| Compound | Typical research dose | Reconstitution | Storage |
|---|---|---|---|
| Tirzepatide | 0.25–2.0 mg (SC weekly) | Bacteriostatic water | 2–8°C after reconstitution |
| Retatrutide | 0.25–1.2 mg (SC weekly) | Bacteriostatic water | 2–8°C after reconstitution |
| Semaglutide | 0.25–2.4 mg (SC weekly) | Bacteriostatic water | 2–8°C after reconstitution |
| Property | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Solubility | Water-soluble | Water-soluble | Water-soluble |
| logP | ~ 4.8 | ~ 4.9 | ~ 4.5 |
| pKa | ~ 4.2 | ~ 4.3 | ~ 4.1 |
| Isoelectric point (pI) | ~ 5.0 | ~ 4.9 | ~ 4.7 |
| Molecular weight | 4813.5 Da | ≈ 4840.6 Da | 4113.6 Da |
HPLC-verified, COA per batch. Tell us the quantity you need.
Showing all 8 resultsSorted by popularity
End of content
End of content